Omega Funds

Profile

Creating and investing in life sciences companies that target our world's most urgent medical needs.

We chose the last letter of the Greek alphabet Ω as our brand because we start our investment process by focusing on the end goal - delivering impactful medicines to patients.

Our investment process starts by focusing on how we can deliver impactful medicines to patients.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.

Early seed or late stage public financing. Large markets or rare diseases.

Established targets or novel technologies.

We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories.

We focus on great people and great science everywhere, with a special concentration on North America and Western Europe.
Our investment decisions are honed by cross-disciplinary teams analyzing platforms and products across disease areas.

We work in partnership with our companies’ founders, management teams and fellow co-investors to provide necessary resources: domain knowledge and perspective, network connectivity, and capital.

Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation.

Omega Funds has invested in more than 150 innovative life sciences companies since its inception. Those investments have led to 46 marketed products, many changing the course of treatment for patients with devastating diseases such as acute lymphoblastic leukemia, melanoma, and Huntington’s disease.